Telomerase Inhibitor: Promising Target Therapy for Cancer
DOI:
https://doi.org/10.55175/cdk.v45i4.805Kata Kunci:
Cancer therapy, molecular therapy, telomerase, telomeresAbstrak
The key to selectively targeting cancer cells is to exploit some basic differences with their normal precursors. One such difference is the activity of the enzyme telomerase. Some studies targeted telomerase and telomeres in order to block limitless replicative potential of cancer cells, providing a fascinating strategy for a broad-spectrum cancer therapy. Telomerase based therapies could be well tolerated and perhaps with minimal side effect on telomerase-competent stem cells.
Kunci pengobatan selektif sel kanker adalah dengan memanfaatkan beberapa perbedaan mendasar antara prekursor sel kanker dan sel normal tubuh. Salah satu perbedaannya adalah aktivitas enzim telomerase. Beberapa penelitian sudah menargetkan telomerase dan telomer sebagai target terapeutik untuk memblokir potensi replikasi sel kanker yang tak terbatas, sebagai strategi terapi kanker spektrum luas. Terapi berbasis telomerase ini dapat ditoleransi dengan baik dan memiliki efek samping minimal pada telomerase sel normal tubuh lainnya.
Unduhan
Referensi
Andrews LG TT. Methods of telomerase inhibition. Methods Mol Biol. 2008;405:1-8.
Berardinelli F, Coluzzi E, Sgura A, Antoccia A. Targeting telomerase and telomeres to enhance ionizing radiation effects in in vitro and in vivo cancer models. Mutat Res. 2017;773:204-19.
Shay JW. Gene-based therapies for cancer. Houston, TX, USA: Springer New York Dordrecht Heidelberg London; 2010 .p. 231-49.
Cheung DH, Ho ST, Lau KF, Jin R, Wang YN, Kung HF, et al. Nucleophosmin interacts with PIN2/TERF1-interacting telomerase inhibitor 1 (PinX1) and attenuates the PinX1 inhibition on telomerase activity. Scientific reports. 2017;7:43650.
Gellert GC, Jackson SR, Dikmen ZG, Wright WE, Shay JW. Telomerase as a therapeutic target in cancer. Drug Discovery Today: Disease Mechanisms. 2005;2(2):159-64.
Jafri MA, Ansari SA, Alqahtani MH, Shay JW. Roles of telomeres and telomerase in cancer, and advances in telomerase-targeted therapies. Genome Med. 2016;8(1):69.
Ruden M, Puri N. Novel anticancer therapeutics targeting telomerase. Cancer Treat Rev. 2013;39(5):444-56.
Shay JW, Keith WN. Targeting telomerase for cancer therapeutics. Br J Cancer. 2008;98(4):677-83.
Tian X, Chen B, Liu X. Telomere and telomerase as targets for cancer therapy. Appl Biochem Biotechnol. 2010;160(5):1460-72.
Folini M, Colella G, Villa R, Lualdi S, Daidone MG, Zaffaroni N. Inhibition of telomerase activity by a hammerhead ribozyme targeting the RNA component of telomerase in human melanoma cells. J Invest Dermatol. 2000;114(2):259-67.
Mo Y, Gan Y, Song S, Johnston J, Xiao X, Wientjes MG, et al. Simultaneous targeting of telomeres and telomerase as a cancer therapeutic approach. Cancer Res. 2003;63(3):579-85.
Dikmen ZG, Ozgurtas T, Gryaznov SM, Herbert BS. Targeting critical steps of cancer metastasis and recurrence using telomerase template antagonists. Biochim Biophys Acta. 2009;1792(4):240-7.
Shay JW, Wright WE. Semin Cancer Biol. 2011;21(6):349–53. doi: 10.1016/j.semcancer.2011.10.001.
Unduhan
Diterbitkan
Cara Mengutip
Terbitan
Bagian
Lisensi
Hak Cipta (c) 2018 https://creativecommons.org/licenses/by-nc/4.0/
Artikel ini berlisensi Creative Commons Attribution-NonCommercial 4.0 International License.
